Repatha Drug Interactions





Zuellig Pharma
Full Prescribing Info
Drug Interactions
No interaction studies have been performed.
The pharmacokinetic interaction between statins and evolocumab was evaluated in the clinical trials. An approximately 20% increase in the clearance of evolocumab was observed in patients co-administered statins. This increased clearance is in part mediated by statins increasing the concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) which did not adversely impact the pharmacodynamic effect of evolocumab on lipids. No statin dose adjustments are necessary when used in combination with evolocumab.
No studies on pharmacokinetic and pharmacodynamics interaction between evolocumab and lipid-lowering medicinal products other than statins and ezetimibe have been conducted.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in